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Background: Few studies on whether etiologic subtype can predict outcome in mild stroke are available. The
study aim to explore the effect of different etiologic subtype on prognosis of these patients.
Methods: We prospectively registered consecutive cases of acute ischemic stroke from September. 01, 2009 to
August. 31, 2011. Patients with National Institute of Health Stroke Scale (NIHSS) ≦3 and within 30 days of symptom
onset were included. All cause death or disability (defined as modified Rankin Scale >2) were followed up at
3 months. The multivariate logistical regression model was used to analyse relationship between etiologic subtype
and clinical outcomes.
Results: We included 680 cases, which accounted for 41.1% (680/1655) of the total registered cases. Mean age
were 62.54 ± 13.51 years, and males were 65.4%. The median time of symptoms onset to admission was 72 hours.
3.8% (26/680) of cases admitted within 3 hours and 4.7% (32/680) admitted within 4.5 hours. However, no patient
received intravenous thrombolysis. Of included patients, 21.5% large-artery atherosclerosis, 40.6% small-vessel
disease, 7.5% cardioembolisms, 2.2% other causes and 28.2% undetermined causes. The rate of case fatality and
death/disability was 2.2% and 10.1% respectively at 3 months. After adjustment of potential confounders, such as
age, sex, NIHSS on admission and vascular risk factors et al., cardioembolism (RR = 3.395;95%CI 1.257 ~ 9.170) was
the predictor of death or disability at 3 months and small vessel occlusion (RR = 0.412;95%CI 0.202 ~ 0.842) was the
protective factor of death or disability at 3 months.
Conclusion: Different etiologic subtype can predict the outcome in patients with mild stroke and it can help to
stratify these patients for individual decision-making.
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It is very common that acute ischemic stroke patients
have mild symptoms or rapidly improving stroke symp-
toms, which makes the decisions of treatment in di-
lemma. Intravenous thrombolysis with recombinant
tissue plasminogen activator (IV rtPA) is proven to be
the most effective treatment for acute ischemic stroke
[1,2]. However, only 1%-5% patients are treated with IV
rtPA. In addition to the narrow time window for treat-
ment, not treat patients with mild or rapidly improving
symptoms is one important reason [3]. In studies evalu-
ating eligibility for thrombolysis, up to 43% of patients* Correspondence: wyplmh@hotmail.com
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reproduction in any medium, provided the orwith mild or improving stroke symptoms do not receive
thrombolytic therapy because of clinicians think the nat-
ural course of these patients is benign [4]. However, ac-
cording to recent reports, 15%–31% of patients with
mild or rapidly improving symptoms have dependent or
dead during hospital admission without thrombolysis
[3,5-7]. Therefore, early identification of these patients
with poor outcome will contribute to the choice of early
intervention to prevent the occurrence of poor out-
comes. Studies suggest that mild stroke patients with
large vessel occlusion are at a high risk for early neuro-
logical deterioration or poor outcome [8]. Imaging with
advanced MRI is one possibility to guide treatment deci-
sion in mild stroke [9-11]. Therapies directed at the
underlying mechanism will be more effective. But there
is still lack of clinical outcomes in patients with different. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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characteristics and explore the effect of different etio-
logic subtype on prognosis of mild stroke.
Methods
Subjects
Due to this is an observational study that will only assess
outcomes in participants, all participants or their desig-
nated relatives provided verbal informed consent for
obtaining relative prognostic information. This research
project was approved by the Scientific Research Depart-
ment of West China Hospital, which conformed to the
local ethic criteria for human researches. We included
acute ischemic stroke admitted consecutively to neuro-
logical wards of the West China Hospital, Sichuan Uni-
versity within 30 days of symptom onset between
September. 01, 2009 to August. 31, 2011. All patients
had a clinical diagnosis of stroke according to World
Health Organization (WHO) criteria and intracranial
hemorrhage were further excluded by CT or MRI scan
in the hospital [12]. Patients with National Institute of
Health Stroke Scale (NIHSS)≦3 were included [13] in
this study.
Data collection
Details of patient demographies, vascular risk factors,
Blood pressure (BP) on admission, laboratory test, brain
image data and complications were recorded at the time
of assessment using a standardized structured form. Vas-
cular risk factors included hypertension (HTN), diabetes,
dyslipidemia, coronary heart disease (CHD), history of
stroke, status of smoking and alcohol. Severity of stroke
was assessed using the NIHSS score. Medical complica-
tions include respiratory infection, urinary tract infec-
tion, electrolyte disturbances, hemorrhage of digestive
tract and epilepsy. Determination of ischemic stroke eti-
ology was according to the Trial of Org 10172 in Acute
Stroke Treatment (TOAST) criteria: large-artery athero-
sclerosis (LAA); small artery occlusion (SAO); cardioem-
bolism (CE); stroke of other determined cause (OC); and
stroke of undetermined cause (UND) [14].
Assessment of outcome
The main outcomes were death and disability at 3 month
after onset. Death was all-cause case fatality. Disability
was defined as modified Rankin Scale (mRS) > 2 [15].
Patients were followed-up by telephone call, clinic inter-
view or letter inquiry. To ensure the quality of informa-
tion collection, all investigators received training in the
beginning according to our standard operational manual.
All data were recorded in a structured data sheet. The
outcome assessors were blinded to the information of
patients. The poor outcome defined as death or disabil-
ity (mRS >2) at 3 months.Statistical analysis
Differences between two groups were tested using t test,
Mann–Whitney U test or Chi-Square test where appro-
priate. Variables that were identified as significant in the
univariate analyses (P <0.10) were entered into multi-
variate logistic regression analyses. The multivariate
logistical regression was used to analyze association be-
tween different etiologic subtype and clinical outcomes,
adjusting for all potential confounders including age,
sex, NIHSS on admission, vascular risk factors and com-
plications et al. Data are reported with Relative Risk
(RR) and 95% confidence intervals (CI). All statistical
analyses were performed with SPSS for Windows,
Version 16.0 (SPSS Inc.).
Results
Baseline characteristics
We included 1655 patients with acute ischemic stroke
within 30 days of symptom onset. Of them, patients with
mild stroke accounted for 41.1% (680/1655). The mean
age was 62.54 ± 13.51 years (18–97 years). Males ac-
counted for 65.4% (445/680). The median time of symp-
toms onset to admission was 72 hours (2–270 hours). The
median of NIHSS on admission is 2(1–3). Of these pa-
tients, 21.5% large-artery atherosclerosis, 40.6% small-
vessel disease, 7.5% cardioembolisms, 2.2% other causes
and 28.2% undetermined causes. 3.8% (26/680) of cases
admitted within 3 hours and 4.7% (32/680) admitted
within 4.5 hours. However, no patient received rt-PA
treatment. The common complications were 7.7% respira-
tory tract infection, 2.0% urinary tract infection, 2.2% elec-
trolyte imbalances, 0.9% gastrointestinal bleeding and
0.4% secondary epilepsy. The proportion of case fatality
and death/disability was 2.2% and 10.1% respectively at
3 months. In order to analyze the effect of specific etiology
on prognosis of minor stroke, such as cardioembolisms,
large-artery atherosclerosis, small-vessel disease, the pa-
tients with undetermined etiology were excluded from the
following analysis. In addition, other causes were also ex-
cluded due to few patients were included in our study. So
we keep a total of 453 cases for further analysis. Com-
pared to patients without death or disability, patients with
poor outcome were younger, had higher proportions of
large-artery atherosclerosis or cardioembolisms and had
high rate of complications of respiratory and urinary tract
infection. Baseline characteristics of this cohort were
described in Table 1.
The influence of etiologic subtype on outcomes at
3 month
After adjustment of potential confounders, such as age,
sex, NIHSS on admission and vascular risk factors et al.,
cardioembolism was the independent predictor of death
or disability at 3rdmonth (RR = 3.395;95%CI 1.257 ~









Age, years 68.84 ± 10.03 63.34 ± 12.61 0.006
Male, % 25(58.1) 257(68.9) 0.153
Time from onset, h 48 48 0.418
SBP on admission, mmHg 141.88 ± 25.96 143.40 ± 21.38 0.667
DBP on admission, mmHg 83.28 ± 16.99 84.13 ± 13.64 0.708
Hypertension, % 26(60.5) 222(59.5) 0.905
Diabetes mellitus, % 11(25.6) 70(18.8) 0.285
Dyslipidemia, % 3(7.0) 31(8.3) 1.000
Coronary heart diseas, % 2(4.7) 22(5.9) 1.000
History of ischemic stroke, % 1(2.3) 22(5.9) 0.493
History of hemorrhagic stroke 2(4.7) 3(0.8) 0.086
Alcohol, % 6(14.0) 80(20.3) 0.251





Respiratory infection, % 10(23.3) 20(5.4) 0.000
Urinary tract infection, % 3(7.0) 5(1.3) 0.040




Epilepsy, % 1(2.3) 1(0.3) 0.196
LAA: large-artery atherosclerosis.
SAO: small artery occlusion.
CE: cardioembolism.
Table 2 Multivariate logistic analysis of the influence of
cardioembolism on death/disability
Variates RR 95% CI P value
Age 1.037 1.003 ~ 1.073 .031
Gender .628 .276 ~ 1.426 .266
Time from onset 1.002 1.000 ~ 1.004 .107
SBP on admission .992 .969 ~ 1.015 .486
DBP on admission 1.008 .972 ~ 1.045 .668
Hypertension 1.313 .610 ~ 2.826 .486
Diabetes mellitus 1.263 .533 ~ 2.989 .596
Hypercholesterolemia 1.188 .317 ~ 4.448 .798
Coronary heart diseas .321 .060 ~ 1.708 .183
History of ischemic stroke .228 .025 ~ 2.070 .189
History of hemorrhagic stroke 11.297 1.469 ~ 86.889 .020
Alcohol .619 .208 ~ 1.848 .390
Smoking 1.620 .644 ~ 4.072 .305
CE VS. Non-CE 3.395 1.257 ~ 9.170 .016
Complications 3.405 1.527 ~ 7.596 .003
CE: cardioembolism.
Table 3 Multivariate logistic analysis of the influence of
SAO on death/disability
Variates RR 95% CI P value
Age 1.035 1.002 ~ 1.069 .039
Gender .614 .270 ~ 1.398 .245
Time from onset 1.001 .999 ~ 1.003 .306
SBP on admission .987 .965 ~ 1.010 .256
DBP on admission 1.014 .978 ~ 1.051 .449
Hypertension 1.428 .659 ~ 3.095 .367
Diabetes mellitus 1.276 .536 ~ 3.041 .582
Hypercholesterolemia 1.114 .301 ~ 4.124 .871
Coronary heart diseas .437 .088 ~ 2.170 .311
History of ischemic stroke .265 .029 ~ 2.425 .240
History of hemorrhagic stroke 12.420 1.423 ~ 108.367 .023
Alcohol .628 .209 ~ 1.886 .407
Smoking 1.600 .630 ~ 4.063 .323
SAO VS. Non-SAO .412 .202 ~ .842 .015
Complications 3.477 1.536 ~ 7.869 .003
SAO: small artery occlusion.
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independent predictor of good outcome at 3rd month
(RR = 0.412;95%CI 0.202 ~ 0.842) (Table 3). Large-artery
atherosclerosis was not the independent predictor of
death or disability, but had a trend of increasing death/
disability (RR = 1.497; 95%CI 0.723 ~ 3.102) (data not
shown). In addition, age, history of intracerebral hemor-
rhage and complications were independent predictive
factor for death or disability at 3rd month across differ-
ent etiologic subtype analysis.
Discussion
In this study, we found patients with mild stroke ac-
counted for 41.1% in our cohort. The proportion of case
fatality and death/disability was 2.2% and 10.1% respect-
ively at 3 month. Different etiologic subtype can predict
the outcome in these patients.
Previous studies showed the proportion of mild stroke
veried from 5.8% to 62.3% based on different criteria,
which in accordance with our study [16,17]. Khatri et al.suggests that approximately one third of so-called mild
strokes have significant disability (mRS 2–6) that persists
at 3 months [7]. In contrast, we found 10.1% of minor
stroke had death or disability. The reasons of low pro-
portion of our study may be as follows: (1) they used the
NIHSS≦5 as criteria whereas we used NIHSS≦3, which
indicates they included participants more severer than
ours; (2) they measured disability with mRS > 1 whereas
we defined it as mRS > 2; (3) they enrolled patients
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30 days, which means their participants may be prone to
have early worsening or early recurrence than ours; (4) In
general, the death or disability of acute ischemic stroke
patients in China is lower than abroad [18,19], so may be
minor stroke no exception.
Several studies reported the predictors of poor out-
come of mild stroke, such as age, diabetes, coronary
heart disease, smoking, and vessel stenosis or occlusion
were predictor of death or disability or recurrence at the
end of follow up period [20-25]. Ferrari J et al. found
hypertension, diabetes, cardiac decompensation, acute
infection, and stroke etiology (LAA and CE) emerged as
independent risk predictors for early deterioration in pa-
tients with a transient ischaemic attack (TIA) or minor
ischemic stroke, defined by an NIHSS score <4 [26]. In
our cohort, age, history of intracerebral hemorrhage, in-
fections and etiologic subtype (CE and SAO) were the
independent predictors of death or disability at 3rd
month. Our finding of etiologic subtype can predict out-
come in mild stroke is more compelling, because con-
secutive subjects that were assessed beyond hospital
discharge at 90 days. So far, although there are no identi-
cal variates for predicting the poor outcome of patients
with minor stroke, future studies are needed to focus on
how to really identify minor stroke patients with poor
outcome by clinical features combined with imaging fea-
tures. Recently, Strbian D et al. indicates that half of pa-
tients presenting with NIHSS 0–6 developed an
infarction despite thrombolysis, and 40% had poor out-
come. Perhaps, urgent multimodal imaging can help to
identify mild stroke at risk of worsening [27]. As we
known, etiologic subtype help stratify patients for sec-
ondary prevention and it may also be used for identifing
poor outcome in patients with mild stroke.
At present, whether patients presenting with mild
stroke should or should not be treated with intravenous
rtPA is still unclear. In our study, 3.8% (26/680) of cases
admitted within 3 hours and 4.7% (32/680) admitted
within 4.5 hours. However, no patient received intraven-
ous thrombolysis. In the light of the natural history of
course of mild stroke is not always benign, before a large
randomized trial proving its lack of benefit in mild
stroke patients, IV t-PA should be considered in these
patients.
Our study has several limitations. (1) It was performed
in a single-center, which may not represent for whole
Chinese population; (2) there is no consensus definition
of mild stroke. The National Institute of Neurological
Disorders and Stroke (NINDS) rtPA study and the Euro-
pean Cooperative Acute Stroke Study (ECASS) III both
excluded patients with mild stroke, but they failed to
clearly define a certain threshold for a mild stroke. We
used diagnostic criteria NIHSS score ≦3, which beevaluated as the more suitable cutoff point [13]; (3) The
effects of potential unknown confounders cannot be
ruled out in our cohort. Despite these limitations, our
study explored the relationship between etiologic sub-
type and outcomes by inclusion of propectively consecu-
tive patients and the blind evaluation of the study
outcome.
Conclusions
In conclusion, our study indicates that different etiologic
subtype can predict the outcome in patients with minor
stroke it can help to stratify these patients for individual
decision-making.
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